• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗精神病药物所致帕金森症的病理生理机制

Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.

作者信息

Vaiman Elena E, Shnayder Natalia A, Khasanova Aiperi K, Strelnik Anna I, Gayduk Arseny J, Al-Zamil Mustafa, Sapronova Margarita R, Zhukova Natalia G, Smirnova Daria A, Nasyrova Regina F

机构信息

V. M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Institute of Personalized Psychiatry and Neurology, 192019 St. Petersburg, Russia.

Shared Core Facilities Molecular and Cell Technologies, V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.

出版信息

Biomedicines. 2022 Aug 18;10(8):2010. doi: 10.3390/biomedicines10082010.

DOI:10.3390/biomedicines10082010
PMID:36009557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9405702/
Abstract

Among neurological adverse reactions in patients with schizophrenia treated with antipsychotics (APs), drug-induced parkinsonism (DIP) is the most common motility disorder caused by drugs affecting dopamine receptors. One of the causes of DIP is the disruption of neurotransmitter interactions that regulate the signaling pathways of the dopaminergic, cholinergic, GABAergic, adenosinergic, endocannabinoid, and other neurotransmitter systems. Presently, the development mechanisms remain poorly understood despite the presence of the considered theories of DIP pathogenesis.

摘要

在使用抗精神病药物（APs）治疗的精神分裂症患者的神经不良反应中，药物性帕金森综合征（DIP）是由影响多巴胺受体的药物引起的最常见的运动障碍。DIP的原因之一是调节多巴胺能、胆碱能、γ-氨基丁酸能、腺苷能、内源性大麻素和其他神经递质系统信号通路的神经递质相互作用受到破坏。目前，尽管存在关于DIP发病机制的相关理论，但对其发展机制仍知之甚少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/1efc2abc1fc6/biomedicines-10-02010-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/5da9beda24cc/biomedicines-10-02010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/8155bca07d0a/biomedicines-10-02010-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/b25bda3719e0/biomedicines-10-02010-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/08fc5e669de1/biomedicines-10-02010-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/ce849a68f3cd/biomedicines-10-02010-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/5ce768ba41ec/biomedicines-10-02010-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/1efc2abc1fc6/biomedicines-10-02010-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/5da9beda24cc/biomedicines-10-02010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/8155bca07d0a/biomedicines-10-02010-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/b25bda3719e0/biomedicines-10-02010-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/08fc5e669de1/biomedicines-10-02010-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/ce849a68f3cd/biomedicines-10-02010-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/5ce768ba41ec/biomedicines-10-02010-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dd1/9405702/1efc2abc1fc6/biomedicines-10-02010-g007.jpg

相似文献

1
Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.抗精神病药物所致帕金森症的病理生理机制
Biomedicines. 2022 Aug 18;10(8):2010. doi: 10.3390/biomedicines10082010.
2
Drug-induced parkinsonism.药物性帕金森病。
J Clin Neurol. 2012 Mar;8(1):15-21. doi: 10.3988/jcn.2012.8.1.15. Epub 2012 Mar 31.
3
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.多巴胺转运体成像可预测精神分裂症和帕金森病患者疾病进展模式和对左旋多巴的反应：一项为期 2 年的随访多中心研究。
Schizophr Res. 2014 Feb;152(2-3):344-9. doi: 10.1016/j.schres.2013.11.028. Epub 2013 Dec 25.
4
Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.抗精神病药物相关运动障碍：药物性帕金森综合征与迟发性运动障碍——病理生理学和临床管理的关键差异
Neurol Ther. 2018 Dec;7(2):233-248. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.
5
[¹²³I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism.[¹²³I]FP-CIT 单光子发射计算机断层扫描在药物诱导的帕金森病中的表现。
Schizophr Res. 2012 Aug;139(1-3):40-5. doi: 10.1016/j.schres.2012.06.003. Epub 2012 Jun 20.
6
Treatment Changes and Prognoses in Patients with Incident Drug-Induced Parkinsonism Using a Korean Nationwide Healthcare Claims Database.利用韩国全国医疗保健理赔数据库对新发药物性帕金森综合征患者的治疗变化及预后分析
J Clin Med. 2023 Apr 13;12(8):2860. doi: 10.3390/jcm12082860.
7
Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.并非所有药物性帕金森综合征都相同：药物类别对运动表型的影响。
Neurol Sci. 2017 Feb;38(2):319-324. doi: 10.1007/s10072-016-2771-y. Epub 2016 Nov 16.
8
Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database.药物诱导帕金森病发病时间：利用大型日本不良事件自发报告数据库进行分析。
Biosci Trends. 2022 May 17;16(2):151-157. doi: 10.5582/bst.2022.01115. Epub 2022 Apr 20.
9
Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.在首发精神分裂症患者中，使用[123I] FP-CIT评估纹状体多巴胺转运体结合情况，这些患者有或没有短期抗精神病药物诱发的帕金森综合征。
Psychopharmacology (Berl). 2005 Sep;181(2):401-6. doi: 10.1007/s00213-005-2250-2. Epub 2005 Oct 14.
10
Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients.编码多巴胺受体的候选基因作为精神分裂症患者抗精神病药物所致帕金森症和迟发性运动障碍风险的预测指标
Biomedicines. 2021 Jul 23;9(8):879. doi: 10.3390/biomedicines9080879.

引用本文的文献

1
Beyond Acute Overdoses: A Case of Chronic Clozapine Toxicity With Non-specific Presentation.超越急性过量：一例表现不典型的氯氮平慢性中毒病例
Cureus. 2025 Feb 27;17(2):e79771. doi: 10.7759/cureus.79771. eCollection 2025 Feb.
2
The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation.抗精神病药物所致运动障碍啮齿动物模型的研究进展：补充抗氧化剂的益处
Biomedicines. 2025 Feb 18;13(2):512. doi: 10.3390/biomedicines13020512.
3
Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.

本文引用的文献

1
Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients.编码多巴胺受体的候选基因作为精神分裂症患者抗精神病药物所致帕金森症和迟发性运动障碍风险的预测指标
Biomedicines. 2021 Jul 23;9(8):879. doi: 10.3390/biomedicines9080879.
2
Parkinsonism in the psychiatric setting: an update on clinical differentiation and management.精神科环境中的帕金森综合征：临床鉴别与管理的最新进展
BMJ Neurol Open. 2020 Jan 27;2(1):e000034. doi: 10.1136/bmjno-2019-000034. eCollection 2020.
3
Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.
挪威处方药物的使用与帕金森病风险的相关性：一项药物广泛相关性研究。
Neurology. 2023 Nov 21;101(21):e2068-e2077. doi: 10.1212/WNL.0000000000207899. Epub 2023 Oct 10.
4
Overview of Movement Disorders Secondary to Drugs.药物所致运动障碍概述
Clin Pract. 2023 Aug 18;13(4):959-976. doi: 10.3390/clinpract13040087.
5
Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study.中国药物性帕金森综合征型精神分裂症患者的危险因素、临床关联及社会功能：一项多中心、观察性、真实世界、前瞻性队列研究的横断面分析
Front Pharmacol. 2023 Mar 3;14:1077607. doi: 10.3389/fphar.2023.1077607. eCollection 2023.
6
, and Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism.，以及基因多态性与氟哌啶醇所致帕金森综合征的风险。
Biomedicines. 2022 Dec 13;10(12):3237. doi: 10.3390/biomedicines10123237.
7
Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.细胞因子失衡作为治疗抵抗性精神分裂症的生物标志物。
Int J Mol Sci. 2022 Sep 26;23(19):11324. doi: 10.3390/ijms231911324.
抗精神病药物相关运动障碍：药物性帕金森综合征与迟发性运动障碍——病理生理学和临床管理的关键差异
Neurol Ther. 2018 Dec;7(2):233-248. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.
4
Experimental treatment of antipsychotic-induced movement disorders.抗精神病药物所致运动障碍的实验性治疗
J Exp Pharmacol. 2016 Aug 8;8:1-10. doi: 10.2147/JEP.S63553. eCollection 2016.
5
Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.多巴胺系统在精神分裂症和抑郁症病理生理学中的失调。
Nat Rev Neurosci. 2016 Aug;17(8):524-32. doi: 10.1038/nrn.2016.57. Epub 2016 Jun 3.
6
-NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.-NMDA受体基因杂合子/维生素D受体药理学表型作为缓解帕金森症运动认知障碍的新型治疗靶点。
Drug Chem Toxicol. 2015 Oct;38(4):415-27. doi: 10.3109/01480545.2014.975355. Epub 2015 Sep 4.
7
A review of vitamin D and Parkinson's disease.维生素D与帕金森病综述
Maturitas. 2014 May;78(1):40-4. doi: 10.1016/j.maturitas.2014.02.012. Epub 2014 Mar 5.
8
Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry.多巴胺 D2 受体调节基底神经节回路的解剖和功能平衡。
Neuron. 2014 Jan 8;81(1):153-64. doi: 10.1016/j.neuron.2013.10.041.
9
The role of vitamin D levels and vitamin D receptor polymorphism on Parkinson's disease in the Faroe Islands.维生素 D 水平和维生素 D 受体多态性在法罗群岛帕金森病中的作用。
Neurosci Lett. 2014 Feb 21;561:74-9. doi: 10.1016/j.neulet.2013.12.053. Epub 2014 Jan 3.
10
NMDA-R inhibition affects cellular process formation in Tilapia melanocytes; a model for pigmented adrenergic neurons in process formation and retraction.N-甲基-D-天冬氨酸受体抑制影响罗非鱼黑素细胞中细胞突起的形成；这是一个用于研究有色素的肾上腺素能神经元突起形成和回缩的模型。
Metab Brain Dis. 2014 Jun;29(2):541-51. doi: 10.1007/s11011-013-9447-6. Epub 2013 Nov 17.